St. Jude Creates Department for Pediatric Neurological Diseases, Recruits NIH Veteran to Lead It

For children with rare neurological disorders - conditions like giant axonal neuropathy, juvenile ALS, or severe muscular dystrophies - the treatment landscape is sparse. These diseases are biologically complex, individually rare, and require deep scientific commitment over long timescales. Most pharmaceutical companies cannot justify the investment. Which is why the institutional home for this work matters enormously.

St. Jude Children's Research Hospital announced in March 2026 the creation of a new Department of Genomic and Translational Neuroscience, designed to concentrate research on catastrophic pediatric neurological disorders under one roof. To lead it, the hospital recruited Carsten Bonnemann, MD, from the National Institutes of Health, where he spent years as chief of the Neuromuscular and Neurogenetic Disorders of Childhood Section.

From NIH bench to St. Jude department chair

Bonnemann's career has centered on understanding the genetic and molecular roots of pediatric neuromuscular diseases. At NIH, his research identified a genetic cause of juvenile amyotrophic lateral sclerosis (ALS), advanced understanding of the genetics underlying multiple forms of muscular dystrophy, and led to the first-in-human intrathecal application of AAV gene therapy for giant axonal neuropathy - a progressive condition that destroys nerve fibers throughout the body.

He trained in pediatric neurology at Massachusetts General Hospital and Harvard Medical School, completed a neuromuscular neurology fellowship at Boston Children's Hospital, and conducted postdoctoral research in the molecular genetics of muscular dystrophy. His awards include the MDA Legacy Award for Achievement in Clinical Research and the George Jacoby Award from the American Neurological Association.

The department's structure and mission

The new department houses two existing centers: the Center for Pediatric Neurological Disease Research (CPNDR), which drives basic research into complex pediatric neurological conditions, and the Center for Experimental Neurotherapeutics (CENT), which focuses on accelerating clinical development of promising treatments. Under Bonnemann's leadership, the department will add new initiatives around genomic diagnosis and precision targeting of genetic therapies.

Faculty members include Fernando Alsina, PhD; Xiaoyu Chen, PhD; Richard Finkel, MD; Andrea Gropman, MD; Dolores Irala, PhD; Peter McKinnon, PhD; and Heather Mefford, MD, PhD.

The department advances St. Jude's broader Pediatric Translational Neuroscience Initiative. J. Paul Taylor, MD, PhD, the hospital's executive vice president and scientific director, described the institutional model as integrating laboratory discovery, therapy development, manufacturing, and clinical delivery in a single institution - a structure designed to move from genetic understanding to patient treatment faster than distributed academic collaborations typically allow.

The challenge of rare diseases

Catastrophic neurological disorders in children are, almost by definition, difficult to study. Patient populations are small. Clinical endpoints take years to measure. Gene therapy manufacturing is expensive and technically demanding. And the diseases themselves are often so rare that individual research groups may see only a handful of cases over decades.

St. Jude's model - a well-funded institution that does not bill families for treatment and can sustain long-term research programs without commercial revenue pressure - is one of the few settings where this kind of work can be pursued at scale. But the model also has inherent limitations. Results from a single institution, however well-resourced, need validation across multiple centers and populations. Gene therapies developed for ultra-rare conditions face particular challenges in clinical trial design when patient numbers are extremely small.

The creation of a dedicated department signals institutional commitment, but the translation from research investment to treatments that reach children remains measured in years and decades, not months. The gap between identifying a genetic cause and delivering an effective therapy remains large for most of these conditions, and the history of gene therapy includes both remarkable successes and sobering setbacks.

Still, for families affected by these disorders, the concentration of expertise, resources, and institutional will in a single department represents a meaningful step. The work that Bonnemann began at NIH will continue at St. Jude with broader infrastructure and a mandate to move from discovery toward treatment.